Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register

How Companies in Myanmar Can Source Pharma Products & CDMO Services from India

Myanmar • Source Pharma Products & CDMO Services from India

Mitul Agarwal
Written by Mitul Agarwal · B.Pharm, MBA
Founder & Head of Business Development · 25+ years in international pharmaceutical BD&L
Published 5 December 2025 · Reviewed and updated 14 December 2025
How Companies in Myanmar Can Source Pharma Products & CDMO Services from India

Introduction

Myanmar has a growing Pharmaceutical Market. It has increasing needs for essential medicines and the treatment of chronic diseases, antibiotics and hospital supplies as well as pediatric formulations. Myanmar imports many of its medicines because it lacks manufacturing capability and demand continues to increase. Of all the countries exporting pharmaceuticals and other products, India is Myanmar’s most trusted partner.

India is an affordable source of WHO-GMP products. India has competitive pricing, stable supply and extensive knowledge of Myanmar's regulatory environment through the Myanmar Food and Drug Administration (MFDA) /FDA. This will benefit Myanmar's distributors, importers, hospitals and procurement agencies in sourcing Pharmaceuticals and CDMO services from India compliantly and efficiently.

Why source from india

Why Myanmar Imports Pharmaceuticals From India

1. WHO-GMP Manufacturing & Global Certifications

India is home to advanced facilities certified under:

  • WHO-GMP
  • USFDA
  • EU-GMP
  • MHRA
  • PIC/S

These align well with Myanmar FDA’s import and registration requirements.

2. Cost-Effective Medicines

In addition, India represents a significant price advantage, averaging 30-70% less than the prices of many global suppliers, which is important to Myanmar's cost-conscious public and private sector.

3. Wide Therapeutic Coverage

India supplies all major therapeutic categories needed in Myanmar:

  • Antibiotics and anti-infectives
  • Antimalarials
  • GI medicines
  • Pain & fever
  • Diabetes & hypertension
  • Pediatric formulations
  • Injectables
  • Nutraceuticals
  • Oncology (selected injectables)

4. Strong API & Formulation Capabilities

Myanmar’s limited API production makes India a critical supplier of raw materials.

5. Experience With MFDA Registration

Indian exporters understand:

  • Dossier preparation
  • Stability data
  • Import permit processes
  • Labeling rules
  • Sample submissions

6. Dependable Supply Chain

India supports Myanmar with consistent supply, even during market disruptions or demand spikes.

Pharma categories supply

What Myanmar Commonly Sources From India

1. Essential Medicines

These include:

  • Antimalarials
  • Antibiotics
  • Antipyretics
  • Antihistamines
  • GI therapies

2. Chronic Disease Medicines

High-demand categories:

  • Diabetes
  • Hypertension
  • Lipid management
  • Cardiovascular therapies

3. APIs

For local formulation and compounding:

  • Paracetamol
  • Metformin
  • Diclofenac
  • Omeprazole
  • Cefuroxime
  • Azithromycin

4. Injectables

India supplies:

  • IV antibiotics
  • Oncology vials
  • Small-volume parenterals
  • IV fluids
  • Lyophilized injectables

5. OTC & Nutraceutical Products

Including:

  • Vitamins
  • Herbal supplements
  • Immunity boosters
  • Energy supplements

6. Medical & Hospital Supplies

  • Syringes
  • IV sets
  • Gloves
  • Masks
  • Surgical consumables

How to source pharma products from india

Step-by-Step: How Myanmar Companies Can Source From India

Step 1: Create a clear sourcing requirement

List:

  • Molecule
  • Strength
  • Dosage form
  • Pack size
  • Required quantity
  • Whether product needs registration

Step 2: Shortlist verified Indian manufacturers

Select WHO-GMP–certified companies with:

  • Prior export to Myanmar
  • Strong regulatory documentation
  • Good audit history

Step 3: Request technical documentation

Ask for:

  • COA
  • GMP
  • COPP
  • Batch records
  • Stability data
  • CTD/ACTD dossier

Step 4: MFDA Registration

Myanmar FDA requires:

  • Full dossier submission
  • Samples
  • Stability data (Zone IV)
  • Artwork in English/Burmese (if required)

Step 5: Finalize commercial terms

Discuss:

  • MOQ
  • Price (FOB/CIF)
  • Payment terms
  • Packaging
  • Lead times
  • Private label requirements

Step 6: Plan logistics & customs clearance

Choose air or sea based on urgency and cost.

Logistics from india

Logistics From India to Myanmar

Myanmar has excellent connectivity to India due to geographical proximity.

Major Export Ports in India

  • Kolkata Port
  • Chennai Port
  • Vishakhapatnam Port
  • Mumbai (JNPT)
  • Hyderabad & Delhi airports

Transit Times

Air Freight:

  • 2–5 days (Kolkata/Hyderabad → Yangon)
  • Ideal for APIs, injectables, urgent orders

Sea Freight:

  • 7–15 days (Chennai/Kolkata → Yangon)
  • Very economical for bulk imports

Common challenges and practical solutions

Challenge Solution
Regulatory Delay  Work with suppliers who have existing registrations in Myanmar or nearby ASEAN markets.
Long Lead Time  Order ahead and weekly follow-ups.
Label Issues 

Ask the manufacturer to share artwork proofs to ensure MFDA compliance.

Quality Concerns  Interrogate Samples, COA and stability data.
Cold-chain handling Use GDP-compliant carriers and temperature loggers.

India has mechanisms that are powerful to resolve such problems.

Conclusion

In Summary, India is Myanmar's most reliable, cost-effective Partner for Pharmaceuticals. With WHO-GMP quality, competitive pricing, extensive product availability, and substantial MFDA registration support, Indian manufacturers are providing Myanmar's Healthcare Sector with consistent and compliant access to essential medicines, APIs, injectables and OTC products. For Hospitals, Pharmacies, NGOs, or National Tenders, partnering with India presents a long-term, stable, and regulatory-friendly supply chain model.

 

❓ Frequently Asked Questions (FAQs)

1. Can Myanmar companies import medicines directly from India?

Yes. India is Myanmar’s largest supplier of pharmaceuticals.

2. Do Indian manufacturers support MFDA registration?

Yes. Most Indian exporters have MFDA-ready dossiers and stability data.

3. How long does shipping take?

  • Air: 2–5 days

  • Sea: 7–15 days

4. What are typical MOQs?

  • Tablets: 100k–300k units

  • Injectables: 5k–20k vials

  • APIs: 25–100 kg

5. Are labels required in Burmese?

Some therapeutic categories require Burmese labels; others accept English.

6. Can Indian CDMOs supply private-label products for Myanmar?

Yes — for OTC, herbal, nutraceuticals, and selected pharmaceuticals.

7. What documents are needed for import?

COA, GMP, COPP, COO, invoice, packing list, BL/AWB, stability data, dossier.

8. Are Indian medicines accepted in Myanmar tenders?

Yes. Many tender-winning medicines in Myanmar come from India.

Source Pharma Products & CDMO Services from India — other markets

Disclaimer: The information presented in this article is for informational and educational purposes only. While every effort has been made to ensure data accuracy and reliability, readers are advised to independently verify all figures, regulations, and market insights before making any business or investment decisions.

Planning to register or source in Myanmar?

Tell us the molecule, dosage form and target market. We will come back on the regulatory pathway and whether the project is realistic before you commit anything.

Submit a Requirement Ask a question
Are you a manufacturer rather than a buyer?
If you already hold WHO-GMP, EU-GMP, USFDA or PIC/S approval, you are closer to supplying Myanmar than you probably think.
Supply LATAM & Caribbean
Don't take our word for it
Myanmar's regulator publishes a register of authorised products. Look up any supplier's claims yourself — including ours.
Verify a supplier

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.